Search clinical trials for: CS1001

Total 487 results

Amicus Therapeutics

Completed

A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

Fabry Disease

United States
Amicus Therapeutics

Terminated

Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study

Fabry Disease

United Kingdom, United States, Australia, Brazil, France
Amicus Therapeutics

Completed

A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

Fabry Disease

France, United Kingdom
Asana BioSciences

Terminated

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Prostate Neoplasms, Castration-resistant

United States
Shanghai Kanda Biotechnology Co., Ltd.

Recruiting

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Melanoma

China
Elpiscience Biopharma, Ltd.
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

Neoplasms | Solid Tumor | Malignant Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Study Explore JS001+JS002 in Patients With Advanced Cancer

Advanced Cancer

China
Can-Fite BioPharma

Completed

Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure

Ocular Hypertension | Glaucoma

Israel, Bulgaria
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

NSCLC

China
CStone Pharmaceuticals

Completed

A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas

Lymphoma | Solid Tumor

China
CStone Pharmaceuticals

Active, not recruiting

A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma

Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

China
Xu jianmin

Unknown

A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer

Colorectal Cancer

China
Medexus Pharma, Inc.

Completed

Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

Hemophilia B

United States, France, United Kingdom, India, Israel, Italy, Poland
Renovo

Completed

A Trial to Compare the Efficacy of Two Formulations of Avotermin Against Placebo (RN1006)

Scar Improvement

United Kingdom
IntraBio Inc

Recruiting

N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)

Ataxia Telangiectasia | Louis Bar Syndrome

Spain, United States, Germany, United Kingdom
Chimerix

Terminated

The Chimerix CMX001 Registry (CMX001)

Outcomes | Survival Rates

United States, Belgium, Canada
IntraBio Inc

Completed

N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)

GM2 Gangliosidosis | Tay-Sachs Disease | Sandhoff Disease

United States, Germany, Spain, United Kingdom
Renovo

Completed

Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males

Cicatrix

United Kingdom
Peking Union Medical College Hospital

Not yet recruiting

Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

Oral Squamous Cell Carcinoma

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Gene Therapy for Chinese Hemophilia A (HA)

Hemophilia A | Gene Therapy

China
Cancer Hospital of Guangxi Medical University

Recruiting

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Withdrawn

JS001+IMP4297 in Patients With Advanced Cancer

Advanced Cancer
Jinling Hospital, China

Recruiting

A Study of RC48-ADC Combined With JS001 For Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma (1)

Carcinoma | Upper Tract Urothelial Carcinoma | UTUC

China
Fudan University

Recruiting

Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma

Laryngeal Cancer | Hypopharyngeal Cancer

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer

Biliary Tract Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Gastric or Esophagogastric Junction Adenocarcinoma

China
Amicus Therapeutics

Completed

A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects

Fabry Disease

Australia
Shanghai Junshi Bioscience Co., Ltd.

Terminated

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Renovo

Completed

Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects

Cicatrix | Wound Healing

United Kingdom
Neuracle Science Co., LTD.
Samsung Medical Center; Korea University Anam Hospital; Severance Hospital

Recruiting

A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients

Sudden Sensorineural Hearing Loss | Seneorineural Deafness

Korea, Republic of
Sándor Beniczky

Completed

High Resolution Ultrasound of Scapulae Alatae - a Prospective Case Control Study

Scapula Alata | Scapular Winging

Denmark
Can-Fite BioPharma

Withdrawn

A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee

Osteoarthritis of the Knee

Israel
Can-Fite BioPharma

Terminated

CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis

Rheumatoid Arthritis

Bosnia and Herzegovina, Canada, Israel, Moldova, Republic of, Poland, Romania, Serbia
IntraBio Inc

Completed

N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)

Niemann-Pick Disease, Type C

United States, United Kingdom, Germany, Slovakia, Spain
Chimerix

Completed

Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection

Adenovirus Infection

United States
Emergent BioSolutions

Completed

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)

Smallpox

United States
Chimerix

Completed

Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses

Double-stranded DNA Virus

United States
Chimerix

Terminated

A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304

Adenovirus

United States
Peking University

Recruiting

Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Refractory Metastatic Digestive System Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (JUPITER06)

Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy

China
Rennes University Hospital
Roche Diagnostics

Completed

Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics (ISTCAT)

Anticoagulant | Mild Head Injury | Antiplatelet

France
Shanghai Junshi Bioscience Co., Ltd.
CTI Clinical Trial and Consulting Services; TopAlliance Biosciences, Inc.

Withdrawn

A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies

Malignancies | Previously Treated, Advanced
TopAlliance Biosciences
Shanghai Junshi Bioscience Co., Ltd.; CTI Clinical Trial and Consulting Services

Recruiting

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Metastatic Solid Tumor | Advanced Unresectable Solid Tumor

United States
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Non-small Cell Lung Cancer

China
Fudan University

Unknown

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

Thyroid Cancer

China
University of Chicago
Asphelia Pharmaceuticals

Completed

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

Allergic Rhinitis

United States
Bio-Path Holdings, Inc.

Recruiting

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Acute Myeloid Leukemia (AML)

United States
Vertex Pharmaceuticals Incorporated

Not yet recruiting

Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype

Sickle Cell Disease
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Hematologic Diseases | Genetic Diseases, Inborn | Sickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Thalassemia | Beta-Thalassemia

United States, Italy, Germany, Saudi Arabia
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Hematologic Diseases | Genetic Diseases, Inborn | Hemoglobinopathies | Thalassemia | Beta-Thalassemia

United States, Germany, Italy, United Kingdom, Canada

Search clinical trials for: CS1001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations